Quality and efficiency of statin prescribing across countries with a special focus on South Africa

Findings and future implications

Brian Godman, Iain Bishop, Stephen Campbell, Rickard Malmström, Ilse Truter

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: Statins are recommended first-line treatment for hyperlipidemia, with published studies suggesting limited differences between them. However, there are reports of under-dosing. South Africa has introduced measures to enhance generic utilization. Part one documents prescribed doses of statins in 2011. Part two determines the extent of generics versus originator and single-sourced statins in 2011 and their costs. Results: Underdosing of simvastatin in 2011 with average prescribed dose of 23.7 mg; however, not for atorvastatin (20.91 mg) or rosuvastatin (15.02 mg). High utilization of generics versus originators at 93–99% for atorvastatin and simvastatin, with limited utilization of single-sourced statins (22% of total statins – defined daily dose basis), mirroring Netherlands, Sweden and UK. Generics priced 33–51% below originator prices. Discussion: Opportunity to increase simvastatin dosing through education, prescribing targets and incentives. Opportunity to lower generic prices with generic simvastatin 96–98% below single-sourced prices in some European countries.
Original languageEnglish
Pages (from-to)323-330
Number of pages8
JournalExpert Review of Pharmacoeconomics Outcomes Research
Volume15
Issue number2
DOIs
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
South Africa
Simvastatin
Hyperlipidemias
Sweden
Netherlands
Motivation
Education
Costs and Cost Analysis

Cite this

Godman, Brian ; Bishop, Iain ; Campbell, Stephen ; Malmström, Rickard ; Truter, Ilse. / Quality and efficiency of statin prescribing across countries with a special focus on South Africa : Findings and future implications. In: Expert Review of Pharmacoeconomics Outcomes Research. 2015 ; Vol. 15, No. 2. pp. 323-330.
@article{95854535efb54633902007ff96dbae99,
title = "Quality and efficiency of statin prescribing across countries with a special focus on South Africa: Findings and future implications",
abstract = "Introduction: Statins are recommended first-line treatment for hyperlipidemia, with published studies suggesting limited differences between them. However, there are reports of under-dosing. South Africa has introduced measures to enhance generic utilization. Part one documents prescribed doses of statins in 2011. Part two determines the extent of generics versus originator and single-sourced statins in 2011 and their costs. Results: Underdosing of simvastatin in 2011 with average prescribed dose of 23.7 mg; however, not for atorvastatin (20.91 mg) or rosuvastatin (15.02 mg). High utilization of generics versus originators at 93–99{\%} for atorvastatin and simvastatin, with limited utilization of single-sourced statins (22{\%} of total statins – defined daily dose basis), mirroring Netherlands, Sweden and UK. Generics priced 33–51{\%} below originator prices. Discussion: Opportunity to increase simvastatin dosing through education, prescribing targets and incentives. Opportunity to lower generic prices with generic simvastatin 96–98{\%} below single-sourced prices in some European countries.",
keywords = "PDDs, South Africa, demand-side measures, dosing, drug utilisation, generics, prices, statins",
author = "Brian Godman and Iain Bishop and Stephen Campbell and Rickard Malmstr{\"o}m and Ilse Truter",
year = "2015",
doi = "10.1586/14737167.2015.967221",
language = "English",
volume = "15",
pages = "323--330",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

Quality and efficiency of statin prescribing across countries with a special focus on South Africa : Findings and future implications. / Godman, Brian; Bishop, Iain; Campbell, Stephen; Malmström, Rickard; Truter, Ilse.

In: Expert Review of Pharmacoeconomics Outcomes Research, Vol. 15, No. 2, 2015, p. 323-330.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Quality and efficiency of statin prescribing across countries with a special focus on South Africa

T2 - Findings and future implications

AU - Godman, Brian

AU - Bishop, Iain

AU - Campbell, Stephen

AU - Malmström, Rickard

AU - Truter, Ilse

PY - 2015

Y1 - 2015

N2 - Introduction: Statins are recommended first-line treatment for hyperlipidemia, with published studies suggesting limited differences between them. However, there are reports of under-dosing. South Africa has introduced measures to enhance generic utilization. Part one documents prescribed doses of statins in 2011. Part two determines the extent of generics versus originator and single-sourced statins in 2011 and their costs. Results: Underdosing of simvastatin in 2011 with average prescribed dose of 23.7 mg; however, not for atorvastatin (20.91 mg) or rosuvastatin (15.02 mg). High utilization of generics versus originators at 93–99% for atorvastatin and simvastatin, with limited utilization of single-sourced statins (22% of total statins – defined daily dose basis), mirroring Netherlands, Sweden and UK. Generics priced 33–51% below originator prices. Discussion: Opportunity to increase simvastatin dosing through education, prescribing targets and incentives. Opportunity to lower generic prices with generic simvastatin 96–98% below single-sourced prices in some European countries.

AB - Introduction: Statins are recommended first-line treatment for hyperlipidemia, with published studies suggesting limited differences between them. However, there are reports of under-dosing. South Africa has introduced measures to enhance generic utilization. Part one documents prescribed doses of statins in 2011. Part two determines the extent of generics versus originator and single-sourced statins in 2011 and their costs. Results: Underdosing of simvastatin in 2011 with average prescribed dose of 23.7 mg; however, not for atorvastatin (20.91 mg) or rosuvastatin (15.02 mg). High utilization of generics versus originators at 93–99% for atorvastatin and simvastatin, with limited utilization of single-sourced statins (22% of total statins – defined daily dose basis), mirroring Netherlands, Sweden and UK. Generics priced 33–51% below originator prices. Discussion: Opportunity to increase simvastatin dosing through education, prescribing targets and incentives. Opportunity to lower generic prices with generic simvastatin 96–98% below single-sourced prices in some European countries.

KW - PDDs

KW - South Africa

KW - demand-side measures

KW - dosing

KW - drug utilisation

KW - generics

KW - prices

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=84924532701&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/quality-efficiency-statin-prescribing-across-countries-special-focus-south-africa-findings-future-im-1

U2 - 10.1586/14737167.2015.967221

DO - 10.1586/14737167.2015.967221

M3 - Article

VL - 15

SP - 323

EP - 330

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 2

ER -